annual cash & cash equivalents:
$83.43M+$34.56M(+70.71%)Summary
- As of today (May 23, 2025), AUPH annual cash & cash equivalents is $83.43 million, with the most recent change of +$34.56 million (+70.71%) on December 31, 2024.
- During the last 3 years, AUPH annual cash & cash equivalents has fallen by -$148.47 million (-64.02%).
- AUPH annual cash & cash equivalents is now -72.74% below its all-time high of $306.02 million, reached on December 31, 2019.
Performance
AUPH Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$66.43M-$17.00M(-20.38%)Summary
- As of today (May 23, 2025), AUPH quarterly cash & cash equivalents is $66.43 million, with the most recent change of -$17.00 million (-20.38%) on March 31, 2025.
- Over the past year, AUPH quarterly cash & cash equivalents has increased by +$1.97 million (+3.05%).
- AUPH quarterly cash & cash equivalents is now -83.06% below its all-time high of $392.04 million, reached on September 30, 2020.
Performance
AUPH quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AUPH Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +70.7% | +3.0% |
| 3 y3 years | -64.0% | -49.9% |
| 5 y5 years | -72.7% | -75.8% |
AUPH Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -64.0% | +70.7% | -56.2% | +98.8% |
| 5 y | 5-year | -72.7% | +70.7% | -83.1% | +98.8% |
| alltime | all time | -72.7% | >+9999.0% | -83.1% | >+9999.0% |
AUPH Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $66.43M(-20.4%) |
| Dec 2024 | $83.43M(+70.7%) | $83.43M(+124.6%) |
| Sep 2024 | - | $37.14M(+11.2%) |
| Jun 2024 | - | $33.41M(-48.2%) |
| Mar 2024 | - | $64.46M(+31.9%) |
| Dec 2023 | $48.88M(-48.1%) | $48.88M(+5.3%) |
| Sep 2023 | - | $46.40M(-43.2%) |
| Jun 2023 | - | $81.71M(-8.2%) |
| Mar 2023 | - | $89.00M(-5.5%) |
| Dec 2022 | $94.17M(-59.4%) | $94.17M(+9.4%) |
| Sep 2022 | - | $86.05M(-43.2%) |
| Jun 2022 | - | $151.63M(+14.4%) |
| Mar 2022 | - | $132.54M(-42.8%) |
| Dec 2021 | $231.90M(-14.9%) | $231.90M(+302.7%) |
| Sep 2021 | - | $57.59M(-52.6%) |
| Jun 2021 | - | $121.56M(-22.4%) |
| Mar 2021 | - | $156.59M(-42.5%) |
| Dec 2020 | $272.35M(-11.0%) | $272.35M(-30.5%) |
| Sep 2020 | - | $392.04M(+68.7%) |
| Jun 2020 | - | $232.41M(-15.2%) |
| Mar 2020 | - | $274.21M(-10.4%) |
| Dec 2019 | $306.02M(+159.4%) | $306.02M(+127.5%) |
| Sep 2019 | - | $134.54M(+2.3%) |
| Jun 2019 | - | $131.49M(-6.3%) |
| Mar 2019 | - | $140.36M(+19.0%) |
| Dec 2018 | $117.97M(-28.8%) | $117.97M(+2.7%) |
| Sep 2018 | - | $114.90M(-13.2%) |
| Jun 2018 | - | $132.30M(+0.8%) |
| Mar 2018 | - | $131.23M(-20.8%) |
| Dec 2017 | $165.63M(+317.7%) | $165.63M(+89.2%) |
| Sep 2017 | - | $87.55M(-51.3%) |
| Jun 2017 | - | $179.72M(-9.7%) |
| Mar 2017 | - | $199.07M(+402.1%) |
| Dec 2016 | $39.65M(+588.8%) | $39.65M(+221.5%) |
| Sep 2016 | - | $12.33M(+35.2%) |
| Jun 2016 | - | $9.13M(+161.3%) |
| Mar 2016 | - | $3.49M(-39.3%) |
| Dec 2015 | $5.76M(-74.6%) | $5.76M(-45.7%) |
| Sep 2015 | - | $10.59M(-32.6%) |
| Jun 2015 | - | $15.73M(-17.4%) |
| Mar 2015 | - | $19.04M(-16.1%) |
| Dec 2014 | $22.71M(+1146.9%) | $22.71M(-11.1%) |
| Sep 2014 | - | $25.53M(-34.7%) |
| Jun 2014 | - | $39.09M(-9.7%) |
| Mar 2014 | - | $43.29M(+2277.2%) |
| Dec 2013 | $1.82M(+884.3%) | $1.82M(-59.5%) |
| Sep 2013 | - | $4.50M(+890.9%) |
| Jun 2013 | - | $454.30K(+1260.2%) |
| Mar 2013 | - | $33.40K(-81.9%) |
| Dec 2012 | $185.00K | $185.00K(-35.9%) |
| Sep 2012 | - | $288.50K(-78.6%) |
| Jun 2012 | - | $1.35M(-59.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $3.35M(-43.5%) |
| Dec 2011 | $5.92M(-6.7%) | $5.92M(-19.2%) |
| Sep 2011 | - | $7.33M(-15.2%) |
| Jun 2011 | - | $8.64M(-15.0%) |
| Mar 2011 | - | $10.17M(+60.3%) |
| Dec 2010 | $6.35M(+38.5%) | $6.35M(-9.3%) |
| Sep 2010 | - | $7.00M(+75.9%) |
| Jun 2010 | - | $3.98M(-21.5%) |
| Mar 2010 | - | $5.07M(+10.6%) |
| Dec 2009 | $4.58M(-78.3%) | $4.58M(-21.6%) |
| Sep 2009 | - | $5.85M(-7.4%) |
| Jun 2009 | - | $6.31M(+36.7%) |
| Mar 2009 | - | $4.62M(-78.1%) |
| Dec 2008 | $21.12M(-34.7%) | $21.12M(-20.3%) |
| Sep 2008 | - | $26.49M(-11.1%) |
| Jun 2008 | - | $29.79M(+43.1%) |
| Mar 2008 | - | $20.81M(-35.7%) |
| Dec 2007 | $32.34M(+142.0%) | $32.34M(-9.8%) |
| Sep 2007 | - | $35.85M(-11.2%) |
| Jun 2007 | - | $40.37M(-2.8%) |
| Mar 2007 | - | $41.52M(+210.7%) |
| Dec 2006 | $13.36M(-20.0%) | $13.36M(-14.7%) |
| Sep 2006 | - | $15.67M(+4.0%) |
| Jun 2006 | - | $15.07M(+2.6%) |
| Mar 2006 | - | $14.69M(-12.1%) |
| Dec 2005 | $16.71M(+12.3%) | $16.71M(-13.6%) |
| Sep 2005 | - | $19.33M(+109.5%) |
| Jun 2005 | - | $9.23M(-24.8%) |
| Mar 2005 | - | $12.28M(-17.5%) |
| Dec 2004 | $14.88M(-46.1%) | $14.88M(-30.6%) |
| Sep 2004 | - | $21.45M(-14.6%) |
| Jun 2004 | - | $25.11M(+18.1%) |
| Mar 2004 | - | $21.25M(-23.1%) |
| Dec 2003 | $27.62M(+39.2%) | $27.62M(-34.7%) |
| Sep 2003 | - | $42.29M(+27.3%) |
| Jun 2003 | - | $33.21M(+91.5%) |
| Mar 2003 | - | $17.34M(-12.6%) |
| Dec 2002 | $19.85M(-35.6%) | $19.85M(-49.7%) |
| Sep 2002 | - | $39.45M(-5.1%) |
| Jun 2002 | - | $41.56M(+36.8%) |
| Mar 2002 | - | $30.38M(+80.9%) |
| Dec 2001 | $30.80M(+478.9%) | - |
| Aug 2001 | - | $16.79M(+778.3%) |
| May 2001 | - | $1.91M(-79.9%) |
| Feb 2001 | - | $9.51M(+78.7%) |
| Nov 2000 | $5.32M(+106.2%) | $5.32M(-48.5%) |
| Aug 2000 | - | $10.34M(-2.0%) |
| May 2000 | - | $10.54M(+264.3%) |
| Feb 2000 | - | $2.89M(+12.2%) |
| Nov 1999 | $2.58M | $2.58M(+1828.7%) |
| Aug 1999 | - | $133.80K(>+9900.0%) |
| May 1999 | - | $0.00(-100.0%) |
| Feb 1999 | - | $1.19M |
FAQ
- What is Aurinia Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Aurinia Pharmaceuticals?
- What is Aurinia Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Aurinia Pharmaceuticals quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Aurinia Pharmaceuticals?
- What is Aurinia Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
What is Aurinia Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of AUPH is $83.43M
What is the all time high annual cash & cash equivalents for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals all-time high annual cash & cash equivalents is $306.02M
What is Aurinia Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, AUPH annual cash & cash equivalents has changed by +$34.56M (+70.71%)
What is Aurinia Pharmaceuticals quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of AUPH is $66.43M
What is the all time high quarterly cash & cash equivalents for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals all-time high quarterly cash & cash equivalents is $392.04M
What is Aurinia Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
Over the past year, AUPH quarterly cash & cash equivalents has changed by +$1.97M (+3.05%)